

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinopharm Tech Holdings Limited

國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8156)

CLARIFICATION ANNOUNCEMENT IN RESPECT OF THE CIRCULAR DATED 10 AUGUST 2023

Reference is made to the circular (the “**Circular**”) of Sinopharm Tech Holdings Limited (the “**Company**”) dated 10 August 2023 in relation to, among other things, the proposed share consolidation and proposed change in board lot size. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

The Board would like to clarify that due to inadvertent clerical errors, in the first paragraph under the table on page 9 of the Circular: (i) As at the Latest Practicable Date, the total number of Existing Shares that may be issued upon exercise of the Shares Options to be granted under the scheme mandate limit of the Share Option Scheme shall be “195,537,680” Existing Shares instead of “153,737,680” Existing Shares; and (ii) As a result of the Share Consolidation, the maximum number of the Consolidated Shares which may fall to be issued upon exercise of the Shares Options to be granted under the scheme mandate limit of the Share Option Scheme will be adjusted to “7,821,507” Consolidated Shares instead of “6,149,507” Consolidated Shares.

The above clarification does not affect other information contained in the Circular. Save as disclosed in this announcement, all other information contained in the Circular remains unchanged.

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
CHAU Wai Wah Fred
Executive Director

Hong Kong, 18 August 2023

As at the date of this announcement, the Board comprises Mr. CHAU Wai Wah Fred, Mr. HO Kam Kin and Ms. KWOK Shuk Yi as executive Directors, Dr. CHENG Yanjie as non-executive Director and Mr. LAU Fai Lawrence and Mr. HSU Dong An as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the GEM website at <https://www.hkgem.com> for a minimum period of 7 days from the date of its publication and on the website of the Company at <http://www.sinopharmtech.com.hk>.